PL2588457T3 - Pochodne pirazolochinolinowe jako inhibitory dna-pk - Google Patents

Pochodne pirazolochinolinowe jako inhibitory dna-pk

Info

Publication number
PL2588457T3
PL2588457T3 PL11729377T PL11729377T PL2588457T3 PL 2588457 T3 PL2588457 T3 PL 2588457T3 PL 11729377 T PL11729377 T PL 11729377T PL 11729377 T PL11729377 T PL 11729377T PL 2588457 T3 PL2588457 T3 PL 2588457T3
Authority
PL
Poland
Prior art keywords
inhibitors
dna
pyrazoloquinoline derivatives
pyrazoloquinoline
derivatives
Prior art date
Application number
PL11729377T
Other languages
English (en)
Inventor
Thomas Fuchss
Werner Mederski
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2588457T3 publication Critical patent/PL2588457T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11729377T 2010-07-01 2011-06-24 Pochodne pirazolochinolinowe jako inhibitory dna-pk PL2588457T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010025786A DE102010025786A1 (de) 2010-07-01 2010-07-01 Pyrazolochinoline
EP11729377.9A EP2588457B1 (de) 2010-07-01 2011-06-24 Pyrazolochinolinderivate als dna-pk-inhibitoren
PCT/EP2011/003127 WO2012000632A1 (de) 2010-07-01 2011-06-24 Pyrazolochinoline

Publications (1)

Publication Number Publication Date
PL2588457T3 true PL2588457T3 (pl) 2015-04-30

Family

ID=44627920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11729377T PL2588457T3 (pl) 2010-07-01 2011-06-24 Pochodne pirazolochinolinowe jako inhibitory dna-pk

Country Status (22)

Country Link
US (1) US8802712B2 (pl)
EP (1) EP2588457B1 (pl)
JP (1) JP5411393B2 (pl)
KR (1) KR101921764B1 (pl)
CN (1) CN103080092B (pl)
AU (1) AU2011273968B2 (pl)
BR (1) BR112012033425A2 (pl)
CA (1) CA2804069C (pl)
CY (1) CY1115974T1 (pl)
DE (1) DE102010025786A1 (pl)
DK (1) DK2588457T3 (pl)
EA (1) EA022430B1 (pl)
ES (1) ES2528447T3 (pl)
HR (1) HRP20150030T1 (pl)
IL (1) IL223872A (pl)
MX (1) MX2012014638A (pl)
PL (1) PL2588457T3 (pl)
PT (1) PT2588457E (pl)
RS (1) RS53831B1 (pl)
SG (1) SG186870A1 (pl)
SI (1) SI2588457T1 (pl)
WO (1) WO2012000632A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
US9464085B2 (en) * 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤としての(s)−n−メチル−8−(1−((2’−メチル−[4,5’−ビピリミジン]−6−イル)アミノ)プロパン−2−イル)キノリン−4−カルボキサミドおよびその重水素化誘導体の共結晶
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
JP7247092B2 (ja) * 2017-01-09 2023-03-28 上海瑛派▲薬▼▲業▼有限公司 キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
CN108295070B (zh) * 2018-01-08 2020-08-11 华中农业大学 一种喹啉衍生物在制备肿瘤抑制药物中的用途
JP7590354B2 (ja) 2019-06-10 2024-11-26 ストロ バイオファーマ インコーポレーテッド 免疫調節物質抗体薬物コンジュゲートおよびその使用
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド 5H-ピロロ[3,2-d]ピリミジン-2,4-ジアミノ化合物およびその抗体コンジュゲート
CN114746420A (zh) * 2019-06-17 2022-07-12 苏特罗生物制药公司 用于癌症治疗和诊断的作为Toll样受体(TLR)7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
CN114728909A (zh) * 2019-09-25 2022-07-08 韩国原子力医学院 含有新型三氟甲基苯基吡唑衍生物作为活性成分用于预防或治疗癌症的组合物
KR102663365B1 (ko) * 2019-09-25 2024-05-08 한국원자력의학원 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0556310T3 (da) 1990-11-06 1995-08-21 Pfizer Quinazolinderivater til forhøjelse af antitumoraktivitet
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1648455A4 (en) * 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007015837A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Inhibitors of checkpoint kinases
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
AR073574A1 (es) * 2008-09-10 2010-11-17 Alcon Res Ltd Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad

Also Published As

Publication number Publication date
CA2804069A1 (en) 2012-01-05
US20130150359A1 (en) 2013-06-13
ES2528447T3 (es) 2015-02-10
JP5411393B2 (ja) 2014-02-12
CN103080092B (zh) 2014-12-17
EA022430B1 (ru) 2015-12-30
KR101921764B1 (ko) 2018-11-23
AU2011273968A1 (en) 2013-02-14
SG186870A1 (en) 2013-02-28
EP2588457B1 (de) 2014-11-05
EP2588457A1 (de) 2013-05-08
PT2588457E (pt) 2015-02-05
RS53831B1 (sr) 2015-06-30
BR112012033425A2 (pt) 2020-08-18
CA2804069C (en) 2018-06-12
CY1115974T1 (el) 2017-01-25
EA201300073A1 (ru) 2013-11-29
SI2588457T1 (sl) 2015-03-31
HRP20150030T1 (hr) 2015-03-13
DK2588457T3 (en) 2015-01-12
AU2011273968B2 (en) 2014-11-20
KR20130041139A (ko) 2013-04-24
DE102010025786A1 (de) 2012-01-05
HK1184782A1 (en) 2014-01-30
WO2012000632A1 (de) 2012-01-05
JP2013531663A (ja) 2013-08-08
MX2012014638A (es) 2013-02-07
IL223872A (en) 2016-02-29
US8802712B2 (en) 2014-08-12
CN103080092A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
PL2769980T3 (pl) Pochodna pirazolochinoliny jako inhibitory PDE9
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
IL252108A0 (en) cdk inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
ZA201407554B (en) Dna-pk inhibitors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
PL2588457T3 (pl) Pochodne pirazolochinolinowe jako inhibitory dna-pk
ZA201203326B (en) Imidazopyridine derivatives as jak inhibitors
GB201004179D0 (en) Enzyme inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
GB201004178D0 (en) Enzyme inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
ZA201404533B (en) Quinoline derivatives as pde10a enzyme inhibitors
AU2019222801A1 (en) Glucosylceramide synthase inhibitors
AU2018200675A1 (en) Glucosylceramide synthase inhibitors
GB201018597D0 (en) Inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors